ClinicalTrials.gg
CompletedNCT03294798Updated Apr 1, 2021

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

A Phase 1/2 interventional study of Human Serum Albumin/interferon alpha2b fusion protein and Pegasys in Hepatitis B Virus, sponsored by Tianjin SinoBiotech Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-04-01.

Sponsored by Tianjin SinoBiotech Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2017, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 192 studies in Hepatitis B with a site in China — 39 open to participants now, 49 under way, 1 of them phase 3. Hepatitis B · China.

Enrollment
131st of 136
11 · median 123
Started
2017
with 9 others
Phase 1/2
4 of 192
1 open now
Registered
86th of 192
by date

Among the 192 studies in Hepatitis B with a site in China, this one is the 131st largest by enrollment of the 136 interventional ones that give a count, is one of 10 that started in 2017, is one of 4 in phase 1/2, and was the 86th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

39 of the 192 studies in Hepatitis B with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 192 studies in Hepatitis B with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects. The secondary purposes is to get the PK/PD data in recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects.

Read the detailed description

This is an open-label study that will be conducted at three sites in China to characterize the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein in HBV subjects. Subjects will receive a single dose of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein or active comparator Pegasys at Day 0. A multipule-dose administration in HBV subjects will last 12 weeks after four weeks washout period.

03

Conditions studied

  • Hepatitis B Virus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who have positive HBeAg or HBeAb
  • Must be healthy males or females between 18 to 60 years old
  • Must have a (BMI) of 18 to 30 kg/m2
  • HBV DNA≥2000 IU/mL
  • ≥1.3 and ≤10 ULN

Exclusion criteria

Exclusion Criteria:

  • Administrated a nucleoside analogues (acid) or interferons against virus drugs, , immune regulator before 6 months;Or any other against hepatitis b virus therapy at the same time.
  • Participated in other clinical trials within a month.
  • Allergic to interferon.
  • T-Bil ≥2 . ALB\<35g/L. PT≥4s.
  • Positive -Ab,HEV-Ab,EBV-Ab,CMV-Ab,TPPA,-Ab.
  • Organ transplant patients, except cornea or hair transplantation.
  • Other hepatopathy exclude NAFLD .
  • Drug addiction or alcohol dependence.
  • (except cured cervical carcinoma in situ, BCC, squamous cell carcinoma) except liver history.
  • Serious retinal disease.
  • Active hemorrhagic disease or severe hematopoietic dysfunction or blood coagulation disorder.
  • disease.
  • Uncontrolled diabetes or thyroid disease or beyond grade 2 blood pressure.
  • WBC\<3×109/L or ANC\<1.5 ×109/L or \<90 ×109/L or HGB\<ULN.
  • HCC or AFP>100ng/mL.
  • Chronic kidney disease or sCr>ULN.
  • Lactating women or pregnancy.
  • Cardiovascular and cerebrovascular events within 6 months.
  • Neurological or psychiatric disease or family history.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Human Serum Albumin/interferon alpha2b

    Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.

    Biological: Human Serum Albumin/interferon alpha2b fusion protein

  • Active comparator
    Pegasys

    Pegasys 180 mcg, once per week

    Biological: Pegasys

Interventions

  • BiologicalHuman Serum Albumin/interferon alpha2b fusion protein

    In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.

  • BiologicalPegasys

    In comparator group, each subject will recieve 180mcg once per week.

06

What researchers measure

Primary outcomes

  1. the rates of subjects with the level of HBVDNA≤0 IU/mL after treatment

    HBV DNA

    Time frame: 17 weeks

Secondary outcomes

  1. the rates of HBV DNA level decrease by more than 2log10 at the end of 4 weeks and after treatment

    HBV DNA

    Time frame: 4 weeks and 17 weeks

  2. the recovery rates of ALT after treatment

    ALT

    Time frame: 17 weeks

  3. the negative conversion rates of HBsAg/HBeAg and HBeAg seroconversion rates after treatment

    HBsAg/HBeAg

    Time frame: 17 weeks

  4. the rates of HBsAg decrease from baseline after treatment

    HBsAg

    Time frame: 17 weeks

07

Study locations

1 site
  • Beijing YouAn Hospital, Capital Medical University
    Beijing, Beijing 100069, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Mar 2019, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Sep 27, 2017
StartActual
Jun 13, 2017
Primary completionActual
Mar 15, 2019
CompletionActual
Mar 15, 2021
Last update
Apr 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03294798
Lead sponsor
Tianjin SinoBiotech Ltd.
Responsible party
Sponsor
First posted
Sep 27, 2017
Start date
Jun 13, 2017
Primary completion
Mar 15, 2019
Completion
Mar 15, 2021
Last update
Apr 1, 2021

Study contacts

meixia wang, professor
principal investigator · Beijing YouAn Hospital
jun li, professor
principal investigator · The First Affiliated Hospital with Nanjing Medical University
liang chen, professor
principal investigator · Shanghai Public Health Clinical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion